Start-Up Quarterly Statistics: A Record-Breaking Q2 As Financings Surge

09 Aug 2018

• By Deanna Kamienski

Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.

Start-Up Quarterly Statistics regular column feature image

The second quarter was a record-breaking period with China-focused biopharma start-ups and others raising hundreds of millions of dollars in venture capital. Both the amount of money raised and the number of financings surged between April and June, as more than $4bn in VC cash alone flowed into companies launched within the last four years.

Initial public offerings also broke records with 12 start-ups launching IPOs in the second quarter, bringing the first half 2018 total to 19 after seven start-ups went public in the first quarter. (Also see "Start-Up Quarterly Statistics: Financings Finally Rise In Q1, But Deals Stagnate" - Scrip, 8 May, 2018.) The first half of this year saw 36 drug developers of any vintage go public in the US, with an average return of 20.9%

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

06 May 2025

• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

05 May 2025

• By Mandy Jackson

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.

Finance Watch: Biohaven Gains Up To $600m In Fresh Capital

02 May 2025

• By Mandy Jackson

Public Company Edition: Biohaven secured $250m up front from Oberland Capital to support its future US troriluzole launch after pulling its EU filing. Also, Procaps arranged $130m in private equity and Rezolute grossed $96.9m in a rare follow-on offering, among other financings.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.